Medicines & Treatments
PNC-27 10 mg
Dragon Pharma PNC-27 10 mg – Experimental Peptide for Cancer Cell Necrosis Research ✔ 32-amino-acid synthetic peptide ✔ Targets HDM-2 proteins on cancer cells ✔ Induces necrosis while sparing normal cells ✔ USA domestic shipping available Dragon Pharma PNC-27 10 mg is an experimental synthetic peptide consisting of 32 amino acids that has been studied for its anti-cancer properties in laboratory settings. This peptide combines a fragment of the p53 tumor suppressor protein with a cell-penetrating sequence, creating a compound designed to specifically target cancer cells while leaving healthy cells unaffected. Each vial contains 10 mg of lyophilized PNC-27 in a 2 mL format, requiring reconstitution with bacteriostatic water before use. The unique mechanism of PNC-27 involves targeting HDM-2 proteins on cancer cell membranes, resulting in pore formation and subsequent cell death through necrosis. For related research compounds, explore our peptides category and specifically FOXO4-DRI for studies on cellular senescence. What Makes PNC-27 Valuable in Research? PNC-27 represents a unique approach to cancer research through its selective targeting mechanism. By combining the p53 fragment with a cell-penetrating sequence, this peptide is designed to interact specifically with HDM-2 proteins present on cancer cell membranes. This interaction triggers pore formation, leading to rapid cell death through necrosis while demonstrating selectivity for cancer cells over normal cells. Researchers value PNC-27 for its novel mechanism of action and its potential to provide insights into cancer cell biology. Its ability to induce necrosis specifically in cancer cells makes it a valuable tool for investigating cancer cell vulnerability and developing new therapeutic strategies. For investigators exploring other mechanisms of cellular regulation, Epitalon 50 mg offers complementary research avenues in cellular health and longevity. Current scientific literature on PNC-27 can be accessed through the PubMed database, where researchers can review peer-reviewed studies on its biological activity and experimental applications. Key Research Applications for Dragon Pharma PNC-27 ✔ Investigation of cancer cell death mechanisms ✔ Evaluation of HDM-2 targeting and pore formation ✔ Research on cancer cell selectivity and normal cell sparing ✔ Studies of necrosis pathways in cancer models ✔ Preclinical models of anti-cancer activity For Research Purposes Only PNC-27 10 mg is intended for research use only and is not approved for human consumption. Proper handling, reconstitution, and experimental protocols are essential for reliable results. For studies on cell death mechanisms, DIHEXA 5 mg provides additional research avenues in cellular biology.
Pentadex 350
Trusted Sciroxx Pentadex Source Pentadex 300 is an injectable steroid produced by Genuine Steroids Supplier -Sciroxx Pharmaceuticals. Pentadex is the equivalent of Pharmaceutical grade Steroid Sustanon 250 by Organon or Omnadren 250, it is a testosterone blend by Sciroxx. It is one of the most potent testosterones on the market and Pentadex (Sustanon) is loved by strength athletes and bodybuilders as it helps for muscle growth even for lazy bodybuilders. It is good for beginners or for athletes interested in massive muscles with high androgenic and anabolic effect.
PE 22-28 10 mg
Dragon Pharma PE 22-28: Ultimate Research Peptide for Muscle Growth Dragon Pharma presents its premium research compound, PE 22-28 10 mg, packaged as a high-purity lyophilized powder in a sterile 2 mL vial. Designed for scientific investigation into muscle physiology, this synthetic fragment of the pituitary adenylate cyclase-activating polypeptide (PACAP) has garnered significant interest in the research community for its potential anabolic and metabolic properties. As a trusted manufacturer, Dragon Pharma ensures stringent quality control, offering researchers a reliable and potent product for studying pathways related to hypertrophy, strength, and tissue repair. This guide provides a comprehensive overview for responsible research design involving PE 22-28. What is PE 22-28? PE 22-28 is a synthetic peptide fragment derived from PACAP (1-28). PACAP is a naturally occurring neuropeptide that plays a vital role in various physiological processes, including neurotransmission, metabolism, and cellular growth. The specific 22-28 sequence has been isolated for research due to its proposed binding affinity and activity. While full-length PACAP is involved in broad systemic functions, the PE 22-28 fragment is of particular interest for studies focused on skeletal muscle. Research, such as that cited in scientific literature on PubChem, explores how certain peptide sequences can influence cellular signaling. It is crucial to note that all applications discussed are strictly for non-human, in-vitro research purposes. PE 22-28 Effects and Mechanism of Action In experimental models, PE 22-28 is observed to influence pathways that could be relevant to muscle anabolism and performance. Its proposed mechanism involves interaction with specific receptor sites, potentially modulating signals that affect protein synthesis, glucose metabolism, and cellular energy utilization. Researchers have noted its potential role in promoting a more anabolic environment within muscle tissue, which may support investigations into hypertrophy (muscle growth) and the inhibition of catabolic (muscle-wasting) processes. Furthermore, its impact on metabolic rate and nutrient partitioning makes it a compound of interest for studies on body composition. Unlike traditional anabolic agents, PE 22-28 operates through a unique peptide pathway, offering a different research angle for understanding muscle adaptation and recovery from stress or exertion.
